Pharmacogenomics and adverse drug reactions

被引：7

作者：

Amur, Shashi ^{[1
]}

Zineh, Issam ^{[1
]}

Abernethy, Darrell R. ^{[1
]}

Huang, Shiew-Mei ^{[1
]}

Lesko, Lawrence J. ^{[1
]}

机构：

[1] Ctr Drug Evaluat & Res, Off Translat Sci, Off Clin Pharmacol, PDA, Silver Spring, MD 20998 USA

来源：

PERSONALIZED MEDICINE | 2010年 / 7卷 / 06期

关键词：

adverse drug reaction; CYP; drug label; drug-metabolizing enzymes; drug safety; genetic; genomic; polymorphism; variant; ABACAVIR HYPERSENSITIVITY; CLINICAL-PRACTICE; RATES; TOXICITY; INDUSTRY; HLA-B-ASTERISK-5701; POLYMORPHISMS; TRANSPORTERS; INTEGRATION; BIOMARKERS;

D O I：

10.2217/PME.10.63

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Adverse drug reactions (ADRs) observed during drug development have been the cause for discontinuing development of many drugs. In addition, serious but rare ADRs observed after marketing have led to withdrawal of some drugs. A priori identification of individuals at risk of developing ADRs for a given drug will help develop strategies to reduce the risk for ADRs in these patients. US FDA initiatives and efforts at reducing ADRs to make drugs safer are described, including updating of drug labels to include genomic information intended to reduce ADRs. Pharmacogenomics can also be harnessed to identify individuals at risk of developing serious ADRs and to treat these individuals with alternative therapy, thus converting ADRs that are traditionally considered unavoidable to avoidable ADRs.

引用

页码：633 / 642

页数：10

共 53 条

[1] Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective [J].

Amur, Shashi ;

Frueh, Felix W. ;

Lesko, Lawrence J. ;

Huang, Shiew-Mei .

BIOMARKERS IN MEDICINE, 2008, 2 (03) :305-311

[2]

[Anonymous], 2010, FDAS SENT IN

[3]

[Anonymous], INT C HARM TECHN REQ

[4] Adverse event detection in drug development: Recommendations and obligations beyond phase 3 [J].

Berlin, Jesse A. ;

Glasser, Susan C. ;

Ellenberg, Susan S. .

AMERICAN JOURNAL OF PUBLIC HEALTH, 2008, 98 (08) :1366-1371

[5] Industry funding of the FDA: Effects of PDUFA on approval times and withdrawal rates [J].

Berndt, ER ;

Gottschalk, AHB ;

Philipson, TJ ;

Strobeck, MW .

NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (07) :545-554

[6] GENETIC POLYMORPHISM OF METABOLIC ENZYMES P450 (CYP) AS A SUSCEPTIBILITY FACTOR FOR DRUG RESPONSE, TOXICITY, AND CANCER RISK [J].

Bozina, Nada ;

Bradamante, Vlasta ;

Lovric, Mila .

ARHIV ZA HIGIJENU RADA I TOKSIKOLOGIJU-ARCHIVES OF INDUSTRIAL HYGIENE AND TOXICOLOGY, 2009, 60 (02) :217-242

[7]

*BRIST MYERS SQUIB, COUM PRESCR INF

[8]

CHUNG WH, 2005, PER MED, V2, P225

[9]

Daly AK, 2010, PHARMACOGENOMICS, V11, P607, DOI [10.2217/pgs.10.24, 10.2217/PGS.10.24]

[10] Warfarin Genotyping Reduces Hospitalization Rates Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study) [J].

Epstein, Robert S. ;

Moyer, Thomas P. ;

Aubert, Ronald E. ;

O'Kane, Dennis J. ;

Xia, Fang ;

Verbrugge, Robert R. ;

Gage, Brian F. ;

Teagarden, J. Russell .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (25) :2804-2812

← 1 2 3 4 5 6 →